Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1317-1324

  Desai, Neil ^a   Trieu, Vuong ^a   Yao, Zhiwen ^a   Louie, Leslie ^a   Ci, Sherry ^a   Yang, Andrew ^a   Tao, Chunlin ^a   De, Tapas ^a   Beals, Bridget ^a   Dykes, Donald ^b   Noker, Patricia ^b   Yao, Rosie ^a   Labao, Elizabeth ^a   Hawkins, Michael ^a   Soon Shiong, Patrick ^a  

^a American BioScience Inc   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALBUMIN RECEPTOR; CREMOPHOR; GLYCOPROTEIN; GLYCOPROTEIN GP 60; PACLITAXEL; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CAVEOLA; CELL TRANSPORT; COLON TUMOR; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LD 50; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MORTALITY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; SURVIVAL TIME; TRANSCYTOSIS; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HT29 CELLS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; POLYETHYLENE GLYCOLS; SURVIVAL RATE; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644753906     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1634     Document Type: Article

References (36)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
2. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer lnst Monogr 1993;15:141-7 Review.
3. Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P. Therapeutic response toTaxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 1986;17:137-42.
4. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
5. Rowinsky RK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
6. Brouwer E, Verweij J, De Bruijn P, et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 2000;28:1141-5.
7. Arbuck SG, Canetta R, Onetto N, Christian MC. Current dosage and schedule issues in development of paclitaxel (Taxol). Semin Oncol 1993;20:31-9.
8. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J 1980;280:1353.
9. Gelderblom H, Verweij J, Nooter K. Sparreboom A Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-8. Review.
10. Lorenz W, Reimann H-J, Schmal A, et al. Histamine release in dogs by Cremophor EL® and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7.
11. Peereboom DM, Donehower RC, Eisenhauer EA, et al. Successful re-treatment withTaxol after major hypersensitivity reactions. J Clin Oncol 1993;11:885-90.
12. Physicians' Desk Reference. 53rd ed. New Jersey: Medical Economics Co., Inc.; 1999.
13. Szebeni J, Alving CR, Savay S, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1:721-35.
14. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions fromTaxol. J Clin Oncol 1990;8: 1263-8.
15. Auzenne E, Donate NJ, Li C, et al. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with Taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 2002;8:573-81.
16. Constantinides PP, Lambert KL, Tustian AK, et al. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res 2000;17:175-82.
17. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72 191-202.
18. Terwogt JM, Nuijen B, Huinink WW, Beijnen JH. Alternative formulations of paclitaxel. Cancer Treat Rev 1997;23:87-95.
19. Merisko-Liversidge E, Sarpotdar P, Bruno J, et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996;13:272-8.
20. Sharma A, Mayhew E, Bolcsak L, et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 1997;71: 103-7.
21. Sharma A, Mayhew E, Straubinger RM. Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res 1993;53: 5877-81.
22. Sharma A, Straubinger RM. Novel Taxol formulations: preparation and characterization of Taxol-containing liposomes. Pharm Res 1994;11:889-96.
23. Sharma A, Straubinger RM, Ojima I, Bernacki RJ. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 1995;84:1400-4.
24. Sharma D, Chelvi TP, Kaur J, et al. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res 1996;8:281-6.
25. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235:179-92.
26. Straubinger RM, Sharma A, Murray M, Mayhew E. Novel Taxol formulations: Taxol containing liposomes. J Natl Cancer Inst Monogr 1993;15:69-78.
27. Wang YM, Sato H, Adachi I, Horikoshi I. Preparation and characterization of poly (lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, Taxol. Chem Pharm Bull (Tokyo) 1996;44: 1935-40.
28. Desai NP, Tan C, Magdassi SM, et al. Protein-stabilized nanoparticles as drug delivery vehicles. Transactions of the 23rd Annual Meeting of the Society for Biomaterials; April 1997; New Orleans.
29. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
30. Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of nanoparticle albumin-bound paclitaxel (Abraxane, ABI-007) compared with Cremophor-based paclitaxel (Taxol) in women with metastatic breast cancer: results of a phase III trial. J Clin Oncol 2005;23:7794-803.
31. Tiruppathi C, Naqvi T, Wu Y, et al. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci USA 2004;101:7699-704.
32. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003;284:L187-96.
33. Schubert W, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001;276:48619-22.
34. Kranenburg O, Verlaan I, Moolenaar WH. Regulating c-Ras function, cholesterol depletion affects caveolin association, GTP loading, and signaling. Curr Biol 2001;11:1880-4.
35. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. Review.
36. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.